Unichem Laboratories Limited
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
Key metrics
Price as of 2026-07-17
Stock price
₹589.05
Market cap
4,146 Cr
Stock P/E
16.4
P/B
1.53
Dividend yield
0.0%
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 423 Cr | 416 Cr | 434 Cr | 432 Cr | 446 Cr | 462 Cr | 533 Cr | 587 Cr | 527 Cr | 579 Cr | 521 Cr | 575 Cr |
| Operating expenses (approx.) | 395 Cr | 407 Cr | 328 Cr | 526 Cr | 403 Cr | 405 Cr | 434 Cr | 494 Cr | 504 Cr | 571 Cr | 201 Cr | 516 Cr |
| EBITDA | 28 Cr | 9 Cr | 106 Cr | -94 Cr | 43 Cr | 58 Cr | 99 Cr | 93 Cr | 22 Cr | 8 Cr | 320 Cr | 59 Cr |
| OPM % | 6.6% | 2.1% | 24.4% | -21.8% | 9.7% | 12.4% | 18.6% | 15.8% | 4.3% | 1.4% | 61.5% | 10.2% |
| Other income | 9 Cr | 6 Cr | 11 Cr | 6 Cr | 4 Cr | 9 Cr | 14 Cr | 9 Cr | 7 Cr | 21 Cr | 12 Cr | 23 Cr |
| Interest | 6 Cr | 7 Cr | 6 Cr | 5 Cr | 4 Cr | 5 Cr | 7 Cr | 5 Cr | 7 Cr | 8 Cr | 7 Cr | 9 Cr |
| Depreciation | 29 Cr | 29 Cr | 28 Cr | 27 Cr | 28 Cr | 29 Cr | 31 Cr | 30 Cr | 32 Cr | 31 Cr | 31 Cr | 31 Cr |
| Profit before tax | 2 Cr | -22 Cr | 84 Cr | -126 Cr | 15 Cr | 33 Cr | 62 Cr | 58 Cr | -9 Cr | -11 Cr | 293 Cr | 19 Cr |
| Tax % | 131.6% | -11.9% | -0.0% | -2.7% | 38.3% | 7.6% | 6.5% | 8.4% | -16.1% | -9.9% | 9.9% | 41.9% |
| Net profit | -0.67 Cr | -24 Cr | 84 Cr | -129 Cr | 9 Cr | 30 Cr | 58 Cr | 53 Cr | -10 Cr | -12 Cr | 264 Cr | 11 Cr |
| EPS (₹) | ₹-0.09 | ₹-4.38 | ₹11.93 | ₹-18.37 | ₹1.31 | ₹4.34 | ₹8.22 | ₹7.52 | ₹1.49 | ₹1.69 | ₹37.54 | ₹1.55 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,180 Cr | 1,211 Cr | 1,235 Cr | 1,270 Cr | 1,343 Cr | 1,705 Cr | 2,111 Cr | 2,202 Cr | Sign in for TTM |
| Operating expenses (approx.) | 1,165 Cr | 1,170 Cr | 1,094 Cr | 1,150 Cr | 1,427 Cr | 1,662 Cr | 1,811 Cr | 1,753 Cr | Sign in for TTM |
| EBITDA | 15 Cr | 40 Cr | 141 Cr | 120 Cr | -84 Cr | 43 Cr | 300 Cr | 449 Cr | Sign in for TTM |
| OPM % | 1.3% | 3.3% | 11.4% | 9.5% | -6.3% | 2.5% | 14.2% | 20.4% | Sign in for TTM |
| Other income | 98 Cr | 91 Cr | 50 Cr | 48 Cr | 39 Cr | 32 Cr | 35 Cr | 63 Cr | Sign in for TTM |
| Interest | 8 Cr | 8 Cr | 5 Cr | 6 Cr | 17 Cr | 23 Cr | 21 Cr | 32 Cr | Sign in for TTM |
| Depreciation | 67 Cr | 82 Cr | 84 Cr | 91 Cr | 113 Cr | 113 Cr | 125 Cr | 125 Cr | Sign in for TTM |
| Profit before tax | -60 Cr | -49 Cr | 52 Cr | 23 Cr | -176 Cr | -62 Cr | 155 Cr | 292 Cr | Sign in for TTM |
| Tax % | 57.3% | -24.4% | 33.1% | -48.2% | -14.7% | -14.3% | 11.0% | 13.5% | Sign in for TTM |
| Net profit | -24 Cr | -60 Cr | 34 Cr | 33 Cr | -202 Cr | -70 Cr | 138 Cr | 253 Cr | Sign in for TTM |
| EPS (₹) | ₹-3.38 | ₹-8.55 | ₹4.88 | ₹4.70 | ₹-28.72 | ₹-10.01 | ₹19.53 | ₹35.91 | Sign in for TTM |
| Dividend payout % | — | — | — | 85.8% | — | — | 0.2% | 0.0% | Sign in for TTM |
Sign in for TTM
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 14 Cr | 14 Cr | 14 Cr | 14 Cr | 14 Cr | 14 Cr | 14 Cr | 14 Cr |
| Reserves | 2,606 Cr | 2,517 Cr | 2,543 Cr | 2,604 Cr | 2,421 Cr | 2,348 Cr | 2,422 Cr | 2,689 Cr |
| Borrowings | — | — | — | — | 297 Cr | 219 Cr | 369 Cr | 430 Cr |
| Other liabilities | — | — | — | — | 460 Cr | 588 Cr | 750 Cr | 590 Cr |
| Total liabilities | — | — | — | — | 3,193 Cr | 3,169 Cr | 3,569 Cr | 3,737 Cr |
| Fixed assets (net) | — | — | — | — | 1,255 Cr | 1,194 Cr | 1,279 Cr | 1,204 Cr |
| CWIP | — | — | — | — | 147 Cr | 123 Cr | 31 Cr | 100 Cr |
| Investments | — | — | — | — | 2 Cr | 1 Cr | 0.02 Cr | 0.02 Cr |
| Other assets | — | — | — | — | 1,589 Cr | 1,694 Cr | 2,030 Cr | 2,197 Cr |
| Total assets | — | — | — | — | 3,193 Cr | 3,169 Cr | 3,569 Cr | 3,737 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | — | — | — | -260 Cr | -85 Cr | 17 Cr | -7 Cr | 4 Cr |
| Cash from investing | — | — | — | 100 Cr | 203 Cr | 50 Cr | -241 Cr | 192 Cr |
| Cash from financing | — | — | — | 191 Cr | -81 Cr | -106 Cr | 184 Cr | 2 Cr |
| Net cash flow | — | — | — | 32 Cr | 36 Cr | -39 Cr | -64 Cr | 198 Cr |
| Free cash flow (OCF − Capex) | — | — | — | -387 Cr | -129 Cr | -6 Cr | -144 Cr | -119 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| ROCE % | -2.0% | -1.6% | 2.2% | 1.1% | -7.2% | -2.7% | 6.2% | 10.3% |
| ROE % | -0.9% | 0.0% | 0.0% | 0.0% | -8.3% | 0.0% | 0.0% | 0.0% |
| Debtor days | — | — | — | — | 160 | 131 | — | — |
| Inventory days | — | — | — | — | 428 | 346 | 405 | 462 |
| Days payable | — | — | — | — | 199 | 147 | — | — |
| Cash conversion cycle | — | — | — | — | 388 | 330 | 405 | 462 |
| Debt / equity | — | — | 0.00 | 0.00 | 0.12 | 0.09 | 0.15 | 0.16 |
| Current ratio | — | — | — | — | 2.48 | 2.39 | 2.05 | 2.48 |
| Net debt / EBITDA | 0.00 | 0.00 | 0.00 | 0.00 | — | 1.60 | 0.93 | 0.31 |
Compare with peers
Loading peers…